| J9271 | Injection, pembrolizumab, 1 mg | 17,200 | $40 | $739.6K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 610 | $90 | $52K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,280 | $20 | $47.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 460 | $90 | $41.7K |
| J0897 | Injection, denosumab, 1 mg | 2,040 | $20 | $38.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 310 | $90 | $27.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 260 | $60 | $15.3K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 100 | $90 | $8.3K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 60 | $130 | $8.3K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 130 | $60 | $7.9K |